

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip Furman

Serial No.: 10/618,531

Filed: July 11, 2003

Title: Combination Therapies with L-FMAU for the Treatment of Hepatitis B Virus Infection

Assistant Commissioner for Patents
Washington, DC 20231

August 9, 2004

Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. A copy of the reference is enclosed as well as a copy of the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.


Respectfully submitted,

Susanne Hollinger
Registration No. 51,811KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-3170(Telephone)
404-572-5145 (Facsimile)



CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



Susanne Hollinger

Date: August 9, 2004
TRI 1016

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/618,531
Filing Date	07-11-2003
First Named Inventor	Phillip A. Furman
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	04674.105070 (TRI 1016 US)

Sheet 1 of 1

3408955 /

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		5,486,520		Belleau et al.	1/23/96	
		5,145,677		Von Eichborn et al.	9/8/92	

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**